2 U.S. lawmakers have disclosed 4 VanEck Biotech ETF trades under the STOCK Act — 2 buys and 2 sells between 2021 and 2022. Congress has been evenly split of BBH.
*Notional-weighted price return on lawmakers' disclosed buys of BBH, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2022-03-04 | Thomas Suozzi | SELL | $50K–$100K | $152.66 | $219.64 2026-08-13 | -22.2% rt |
| 2022-01-28 | Donald Sternoff Beyer Jr. | SELL | $1K–$15K | $160.74 | $219.64 2026-08-13 | -15.5% rt |
| 2021-12-22 | Donald Sternoff Beyer Jr. | BUY | $1K–$15K | $190.18 | $219.64 2026-08-13 | +15.5% |
| 2021-10-20 | Thomas Suozzi | BUY | $50K–$100K | $196.19 | $219.64 2026-08-13 | +11.9% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
2 members of the U.S. House and Senate have disclosed VanEck Biotech ETF transactions under the STOCK Act — 2 purchases and 2 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a BBH purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Every BBH trade is marked to the latest close in the Return column; sells matched to a prior buy show a realized round-trip return.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded BBH and how it performed.